Takeda Pharmaceutical (NYSE:TAK) Insider Giles Richard Platford Sells 31,083 Shares

Takeda Pharmaceutical Co. (NYSE:TAK) insider Giles Richard Platford sold 31,083 shares of Takeda Pharmaceutical stock in a transaction on Monday, August 10th. The stock was sold at an average price of $17.10, for a total transaction of $531,519.30. Following the sale, the insider owned 315,838 shares in the company, valued at $5,400,829.80. This represents a 8.96% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Takeda Pharmaceutical Stock Performance

NYSE TAK opened at $17.42 on Thursday. The company has a fifty day moving average of $16.49 and a two-hundred day moving average of $17.13. The company has a market capitalization of $55.82 billion, a PE ratio of 51.24 and a beta of -0.08. Takeda Pharmaceutical Co. has a 1 year low of $12.99 and a 1 year high of $18.90. The company has a debt-to-equity ratio of 0.58, a current ratio of 1.14 and a quick ratio of 0.62.

Takeda Pharmaceutical (NYSE:TAK) last posted its earnings results on Tuesday, March 31st. The company reported $0.56 EPS for the quarter. The business had revenue of $6.90 billion for the quarter. Takeda Pharmaceutical had a return on equity of 10.95% and a net margin of 3.80%. As a group, analysts expect that Takeda Pharmaceutical Co. will post 3.01 earnings per share for the current year.

Analysts Set New Price Targets

TAK has been the topic of a number of research reports. Wall Street Zen raised Takeda Pharmaceutical from a “hold” rating to a “buy” rating in a report on Saturday, July 18th. Zacks Research upgraded Takeda Pharmaceutical from a “strong sell” rating to a “hold” rating in a research note on Tuesday, August 4th. Finally, Weiss Ratings cut Takeda Pharmaceutical from a “hold (c-)” rating to a “sell (d+)” rating in a research note on Thursday, July 30th. Two research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the stock has a consensus rating of “Hold”.

Institutional Trading of Takeda Pharmaceutical

Several hedge funds and other institutional investors have recently made changes to their positions in TAK. Valeo Financial Advisors LLC purchased a new stake in Takeda Pharmaceutical during the second quarter worth about $163,000. GAMMA Investing LLC lifted its position in shares of Takeda Pharmaceutical by 10.7% during the 2nd quarter. GAMMA Investing LLC now owns 13,837 shares of the company’s stock valued at $222,000 after acquiring an additional 1,338 shares during the period. Versant Capital Management Inc boosted its stake in shares of Takeda Pharmaceutical by 10.8% during the 2nd quarter. Versant Capital Management Inc now owns 42,686 shares of the company’s stock worth $684,000 after acquiring an additional 4,169 shares in the last quarter. Parallel Advisors LLC grew its holdings in shares of Takeda Pharmaceutical by 10.5% in the 1st quarter. Parallel Advisors LLC now owns 24,651 shares of the company’s stock worth $457,000 after acquiring an additional 2,343 shares during the period. Finally, Glenmede Trust Co. NA increased its stake in Takeda Pharmaceutical by 9.6% in the 1st quarter. Glenmede Trust Co. NA now owns 30,205 shares of the company’s stock valued at $559,000 after purchasing an additional 2,640 shares in the last quarter. Institutional investors and hedge funds own 9.17% of the company’s stock.

More Takeda Pharmaceutical News

Here are the key news stories impacting Takeda Pharmaceutical this week:

• Neutral Sentiment: The sales were explicitly made to cover tax-withholding obligations tied to the vesting of equity awards, rather than representing discretionary open-market selling. Each insider retained a substantial stake after the transactions, reducing the concern that management is broadly abandoning the company. SEC insider filing
• Negative Sentiment: The volume and seniority of the sellers could weigh on investor sentiment. CEO Julie So-Young Kim sold 89,090 shares, while Andrew Stewart Plump sold 165,393 shares. General Counsel Natalie Anne Marie Furney, Giles Richard Platford, Lauren Rusckowski Duprey and several other insiders also reduced their holdings, with individual ownership declines ranging from about 6.6% to 18.5%. SEC insider filing

Takeda Pharmaceutical Company Profile

Takeda Pharmaceutical Company Limited (NYSE: TAK) is a Tokyo-based, multinational biopharmaceutical company with roots dating back to 1781. The company researches, develops, manufactures and commercializes pharmaceutical and biopharmaceutical products for patients worldwide. Takeda is publicly listed and operates as a fully integrated R&D-driven healthcare company focused on delivering specialty medicines and therapies across a range of therapeutic areas.

Takeda’s main business activities encompass discovery and development of prescription medicines, clinical development and regulatory affairs, manufacturing of small molecules and biologics, and global commercial operations.